The Analyst Landscape: 17 Takes On BioNTech
Analysts have set 12-month price targets for BioNTech, revealing an average target of $132.24, a high estimate of $171.00, ...
pharmaphorum20h
Pfizer, BioNTech's mRNA flu vaccine starts phase 3 testing
The partners are hoping the same rapid development and deployment demonstrated with their COVID-19 vaccine Comirnaty could ... reach the clinic this year. Sanofi has reported positive results ...
Study reveals COVID-19 vaccine safety in patients with atrial fibrillation/flutter
Development of the coronavirus disease 2019 (COVID-19) vaccine has been key to countering the pandemic caused by severe acute ...
Many more seniors are getting COVID shots this year, CDC reports
The data from the CDC's National Immunization Survey estimates that 37.6% of Americans ages 65 and older had gotten a shot of ...
GeoVax Labs: Promising Developments in COVID-19 Vaccine and Therapeutics Propel Buy Rating
Vernon Bernardino, an analyst from H.C. Wainwright, reiterated the Buy rating on GeoVax Labs (GOVX – Research Report). The associated ...
Science Daily7h
An advance toward inhalable mRNA medications, vaccines
Most people don't enjoy getting shots for treatments or vaccines. So, researchers are working to create more medicines, such as those made from messenger RNA (mRNA), that can be sprayed and inhaled. A ...